Obesity
A chronic disease linked to excess body fat — and its relationship with mortality, mapped in the largest available meta-analysis covering over 10 million participants, has the shape of a curve, not a straight line.
Number of studies
1
Safety
High
Time to effects
Improvement in metabolic markers (blood pressure, lipid profile, insulin sensitivity) is often measurable after losing just a few percent of body weight, typically within a few months of consistent intervention.
Who it's for
Table of contents
TL;DR
A chronic disease linked to excess body fat — and its relationship with mortality, mapped in the largest available meta-analysis covering over 10 million participants, has the shape of a curve, not a straight line.
- →Losing 5-10% of body weight is linked in studies to significant improvement in metabolic and cardiovascular markers
- →Maintaining a BMI in the 22.5-25.0 range is linked to the lowest death risk in the largest available meta-analysis
| Condition type | Chronic disease linked to excess body fat |
|---|---|
| Level of evidence | Strong — meta-analyses covering tens of millions of participants |
| Classification | BMI ≥30 (obesity), BMI 25-30 (overweight), BMI 22.5-25 (lowest death risk in large meta-analyses) |
| Lowest death risk | BMI in the range of 22.5-25.0 in the Global BMI Mortality Collaboration analysis |
| Key BMI limitation | Doesn't distinguish muscle from fat mass or assess fat distribution |
| Status | A recognized chronic disease, not merely an aesthetic concern |
Understand
Overview
Obesity is a chronic disease characterized by excessive accumulation of body fat to a degree detrimental to health, most commonly classified using body mass index (BMI, weight in kilograms divided by height in meters squared) — a BMI of 30 or above defines obesity, and 25 to 30 defines overweight. Although BMI is an imperfect tool (it doesn't distinguish muscle mass from fat mass, nor does it account for fat distribution in the body), it remains the most widely used and best-studied population-level indicator of weight-related health risk.
The most compelling picture of exactly how body weight relates to death risk comes from the Global BMI Mortality Collaboration analysis from 2016, pooling individual participant data from 239 prospective studies worldwide — over 10.6 million people in total. The analysis, restricted to never-smokers without chronic disease at baseline (to eliminate reverse-causation effects, where disease causes weight loss rather than the other way around), found the lowest death risk in the BMI range of 22.5-25.0, with risk rising on both sides of that range — but the rise was markedly steeper on the obesity side than on the underweight side. At grade III obesity (BMI 40-60), death risk was nearly three times higher than in the reference range.
Who might genuinely benefit from this knowledge? Practically anyone tracking their body weight in the context of long-term health, but above all people with a BMI over 30, for whom even moderate weight loss (5-10%) is linked in studies to significant improvement in metabolic and cardiovascular markers. It's worth remembering that BMI is a population-level screening tool, not a precise individual diagnosis — a highly muscular athlete can have a high BMI without excess body fat, which is why assessing fat distribution (e.g., waist circumference, waist-to-hip ratio) can be a valuable complement to BMI alone.
Mechanism of action
Obesity develops as a result of chronic positive energy balance — calorie intake exceeding expenditure over an extended period, though the pace of this balance is influenced by a complex network of hormonal, genetic, and behavioral factors, not just 'willpower' alone. Excess energy is stored in adipocytes (fat cells), which under chronic overload undergo hypertrophy and, once a certain capacity is exceeded, begin releasing increased amounts of free fatty acids and pro-inflammatory cytokines (including TNF-alpha, IL-6), contributing to chronic low-grade inflammation and insulin resistance in peripheral tissues.
The distribution of excess body fat is particularly important — visceral fat, accumulating around the internal organs of the abdominal cavity and described in more depth in our visceral fat entry, is far more metabolically active and harmful than subcutaneous fat, because it releases its metabolic byproducts directly into the portal circulation, burdening the liver. This partly explains why two people with identical BMI can have very different metabolic risk profiles, depending on whether their excess fat accumulates mainly viscerally or peripherally.
Chronic positive energy balance
Calorie intake exceeding expenditure leads to the gradual accumulation of excess energy.
Adipocyte hypertrophy
Fat cells store excess energy, growing beyond their optimal capacity.
Release of pro-inflammatory cytokines
Overloaded adipocytes release free fatty acids and cytokines (TNF-alpha, IL-6), driving inflammation.
Development of peripheral tissue insulin resistance
Chronic low-grade inflammation disrupts insulin signaling in muscle and liver.
Evidence: strong — based on 1 study in this database.
Benefits
Common myths
MythBMI is a precise diagnostic tool for every individual.
FactBMI is a useful population-level indicator, but it doesn't distinguish muscle mass from fat mass — a very muscular person can have a high BMI without excess body fat, which is why it's worth supplementing with an assessment of fat distribution.
MythBeing underweight is always safer than being slightly overweight.
FactIn the largest available meta-analysis, the lowest death risk was recorded at a BMI of 22.5-25.0, and clear underweight (BMI below 18.5) was linked to significantly elevated death risk, comparable to moderate overweight.
Practice
Frequently asked questions
The standard WHO classification defines obesity as a BMI of 30 and above, with further division into grades: I (30-35), II (35-40), and III (40 and above), with health risk rising with the grade.
Data from large meta-analyses suggest death risk starts rising already above a BMI of 25, though this rise is milder than with overt obesity — the lowest risk was recorded in the narrow range of 22.5-25.0.
Weight loss, even moderate (5-10%), is linked to real improvement in many health markers, but the best results come from combining it with physical activity, which additionally protects muscle mass and independently supports metabolic health.
What actually helps
Caloric deficit supported by physical activity
Strong evidenceThe fundamental, best-studied intervention — combining calorie intake control with regular movement gives better and more lasting results than diet alone.
Pharmacological treatment (e.g., GLP-1 agonists)
Strong evidenceIn selected patients, under a doctor's supervision, modern medications can significantly support weight loss — the decision is always made by a doctor based on individual assessment.
Bariatric surgery
Strong evidenceConsidered for people with severe obesity, especially with metabolic complications, after conservative treatment has failed.
What to combine with
Good combinations
Strength Training — Strength training helps preserve muscle mass during weight loss and supports metabolic health independently of weight alone
Leptin and Ghrelin — Understanding satiety and hunger hormones helps explain why maintaining weight loss long-term is often harder than losing the weight itself
Safety
Side effects & contraindications
Possible side effects
Obesity, especially with a dominant share of visceral fat, significantly raises the risk of type 2 diabetes, cardiovascular disease, and certain cancers
Grade III obesity (BMI 40-60) was linked in the Global BMI Mortality Collaboration analysis to nearly three times higher death risk than the reference range
Contraindications
No significant contraindications at typical doses.
Is it worth taking?
Who it's for
- People with a BMI over 30, for whom weight loss can significantly reduce health risk
- People with a BMI of 25-30 (overweight) and additional metabolic risk factors
- Anyone tracking their body weight in the context of long-term prevention
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
The Global BMI Mortality Collaboration analysis covered data from over 10.6 million participants across 239 studies on four continents.
At grade III obesity (BMI 40-60), death risk was nearly three times higher than in the BMI 22.5-25.0 range.
Studies
For BMI values above 25.0 kg/m², mortality increased approximately log-linearly with BMI, with the association stronger in younger people and men.
Global BMI Mortality Collaboration, The Lancet, 2016 (meta-analysis of 239 studies, n=10,625,411)
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
Strong evidenceGlobal BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, Kaptoge S, et al. · The Lancet · 2016
A meta-analysis of individual participant data from 239 prospective studies (10,625,411 participants), restricted to never-smokers without chronic disease at baseline, found the lowest death risk at a BMI of 22.5-25.0. Risk rose approximately log-linearly above a BMI of 25.0, reaching HR=2.76 at grade III obesity (BMI 40-60) relative to the reference range.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Related entries
4.6Visceral Fat
Fat tissue that accumulates around the internal organs of the abdominal cavity is metabolically far more active and harmful than subcutaneous fat — even though the two can look similar from the outside.
4.6Metabolic Syndrome
A cluster of five risk factors — from abdominal obesity to elevated triglycerides — that multiplies the risk of type 2 diabetes and cardiovascular disease, but is largely modifiable through lifestyle change.
4.6Leptin and Ghrelin
Two opposing hormones that regulate hunger and satiety — understanding how they work explains why losing weight is physiologically harder than a simple calorie-balance model suggests.
4.5NEAT (Non-Exercise Activity Thermogenesis)
All the energy burned on everyday movement unrelated to formal exercise — fidgeting, standing, gesturing — can differ by as much as 2000 calories a day between individuals, despite no difference in the number of planned workouts.
4.5Adaptive Thermogenesis
A drop in resting energy expenditure beyond what body-mass loss alone would predict — the mechanism explaining why weight loss naturally slows over time, even with a maintained calorie deficit.
4.7Type 2 Diabetes
A chronic metabolic disease in which the body loses its ability to properly regulate blood glucose — and one of the few chronic diseases where a large randomized trial showed that lifestyle change alone can outperform a drug.
4.6Insulin Resistance
A state in which the body's cells respond more weakly to insulin, forcing the pancreas to produce ever-larger amounts of it — the most common, and largely reversible, precursor of type 2 diabetes.
4.6Insulin
A key anabolic hormone regulating blood glucose levels — understanding how it works is the foundation of consciously managing metabolic health, regardless of whether someone has diabetes.
Related articles
AktualnościSemaglutide and GLP-1 drugs: a new era of obesity treatment or a passing fad?
GLP-1 receptor agonists, better known under the brand names used for diabetes and obesity treatment, have changed how medicine approaches weight reduction in recent years. We look at what the clinical trials actually show.
August 11, 2026
PoradnikiIntermittent Fasting and Metabolism: Does Fasting Slow It Down?
"Don't go too long without eating, or your body will enter starvation mode and slow your metabolism" — one of the most commonly repeated warnings against intermittent fasting. A controlled 84-hour fasting study shows the opposite: short-term fasting didn't slow resting energy expenditure, it increased it, driven by more than a doubling of norepinephrine. 'Starvation mode' is a real phenomenon, but it applies to longer, more severe caloric restriction — not a fast lasting hours or even a couple of days.
August 23, 2026
PoradnikiLemon Water on an Empty Stomach: Does It Really Speed Up Metabolism?
"Drink a glass of lemon water right after waking up to kickstart your metabolism" is one of the most repeated pieces of advice online, almost always without a source. The truth is more interesting than the myth itself: there's a solid study showing that plain drinking water genuinely, measurably raises metabolic rate — by as much as 24% within an hour of drinking it. The catch is that no human study has ever tested adding lemon to that water for its effect on metabolic rate or weight loss. This isn't a story about a "debunked myth" — it's about a myth nobody has formally tested, and that distinction matters. In this article we separate the two elements: what water actually does, and why we honestly can't say the same about lemon.
August 24, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.